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Abstract: The main challenges facing efforts to prevent the transmission of human immunodeficiency
virus (HIV) are the lack of access to sexual education services and sexual violence against young
women and girls. Vaginal formulations for the prevention of sexually transmitted infections
are currently gaining importance in drug development. Vaginal mucoadhesive tablets can be
developed by including natural polymers that have good binding capacity with mucosal tissues,
such as chitosan or guar gum, semisynthetic polymers such as hydroxypropylmethyl cellulose,
or synthetic polymers such as Eudragit® RS. This paper assesses the potential of chitosan for the
development of sustained-release vaginal tablets of Tenofovir and compares it with different polymers.
The parameters assessed were the permanence time of the bioadhesion—determined ex vivo using
bovine vaginal mucosa as substrate—the drug release profiles from the formulation to the medium
(simulated vaginal fluid), and swelling profiles in the same medium. Chitosan can be said to allow
the manufacture of tablets that remain adhered to the vaginal mucosa and release the drug in a
sustained way, with low toxicity and moderate swelling that ensures the comfort of the patient and
may be useful for the prevention of sexual transmission of HIV.
Keywords: Human Immunodeficiency Virus; Acquired Immunodeficiency Syndrome; chitosan;
mucoadhesive vaginal tablets; Tenofovir; controlled release; ex vivo bioadhesion; swelling behaviour;
swelling witness microstructure
1. Introduction
Acquired Immunodeficiency Syndrome (AIDS) continues to be one of the main public health
problems around the world, especially in countries with the fewest resources. It is estimated that
36.7 million people are currently living with HIV [1]. The latest available data indicate that significant
progress has been made over the last decade [2–4], and yet HIV continues to highlight the world’s
inequalities. The main challenges in preventing HIV transmission are the lack of access to sexual
education services, and sexual violence against young women and girls [5]. It is, therefore, necessary
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to have methods such as microbicides that are controlled by women themselves in order to prevent
transmission, so they no longer depend on men to prevent the acquisition of the virus.
Tenofovir (TFV) is a drug that acts by blocking reverse transcriptase activity in HIV infection. It is
currently being investigated for its potential microbicidal effect against HIV [6,7]. TFV microbicide
formulations have had proven antiviral efficacy in animal models and are currently in phase III clinical
trials. Recent studies have demonstrated that TFV vaginal administration has no significant cytotoxicity
in women and that TFV has no toxicity for vaginal mucosa at concentrations commonly used as a
microbicide [8,9]. Numerous reports have assessed and confirmed the effectiveness of TFV vaginal
formulations. A wide range of dosage forms containing this drug have been evaluated, including
gels [10,11], films [12,13], and intravaginal rings [14–17].
Solid formulations have the advantage of high dose accuracy and long-term stability, as compared
to semi-solid systems. The polymers used in these formulations must, therefore, be able to adhere to
the vaginal mucosa and modulate drug release from the dosage form. The term “adhesion” describes
the ability of certain macromolecules to adhere to the body’s tissues; when this occurs in mucosa it is
known as mucoadhesion. Although any material can adhere to the mucosa thanks to its viscous nature,
there can be no real bioadhesion without an interrelation between some specific chemical groups in
the polymers and biological tissues, or without establishing an interpenetration of chains. The dosage
forms that bind to mucous membranes are described as mucoadhesive, as their purpose is to remain
fixed at the point where the release and/or absorption of the drug occurs by prolonging its residence
time [18,19].
All bioadhesive systems owe their properties to the inclusion of one or more types of polymeric
molecules which, under appropriate conditions, establish interactions with the biological surface.
One of these polymers is chitosan (CH), a natural, biocompatible, biodegradable, bioadhesive, and
water-soluble polymer that degrades in acidic medium. It is obtained from the deacetylation of chitin,
one of the most abundant polysaccharides in nature, as it is the structural element in the exoskeleton
of crustaceans, such as crabs and shrimps. The amino and hydroxyl groups allow the adhesion to
mucous through hydrogen bonds, and are protonated in an acid medium, which improves adhesion to
negatively charged surfaces such as mucous. This polymer has been widely applied in the development
of different pharmaceutical dosage forms for vaginal administration such as gels and tablets [20–23].
Possibly the most widely studied polymer for the development of such formulations is
hydroxypropylmethyl cellulose (HPMC), a cellulose ether with methyl and hydroxypropyl groups
used for the controlled release of drugs in hydrophilic matrix systems [24]. It is a FDA-approved
polymer found in a wide range of applications, and was initially used in vaginal formulations as an
excipient in the manufacture of films [25,26] and gels [27], although its use in vaginal administration
tablets [20,28–30] has recently become more widespread. Another very similar polymer to HPMC
and CH is guar gum (GG), which is also soluble in water, where it produces a viscous gel. GG is a
biocompatible and biodegradable polysaccharide obtained from the seeds of Cyamopsis tetragonoloba
used in the pharmaceutical industry as a binder or a disintegrant in tablets, and there are also
several references to its use in the development of vaginal dosage forms. GG is sometimes present
in bioadhesive vaginal gels, and has also been combined with HPMC to develop a bioadhesive
vaginal tablet formulation [31,32]. All of the above-mentioned polymers are hydrophilic, and since
the purpose of these formulations is their dissolution in the vaginal environment, it is also worth
mentioning hydrophobic polymers such as Eudragit RS PO® (ERS). This is a copolymer of ethyl
acrylate, methyl methacrylate, and a low content of methacrylic acid ester with quaternary ammonium
groups. The ammonium groups are present as salts and render the polymers permeable. It is insoluble
in aqueous medium and has low permeability and pH-independent swelling [33]. Its inclusion in
pharmaceutical forms of vaginal administration to date is much scarcer than for the polymers described
above, and it is mainly used in nanocapsules, microspheres, and microparticles [21,34,35].
With this background, the aim of this study is to assess the potential of chitosan to develop
sustained release mucoadhesive tablets of TFV, where the drug release from these systems depends
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on the properties of each polymer. These properties are also analysed in other natural, semisynthetic,
and synthetic polymers in order to assess the advantages offered by CH in the development of
these formulations.
2. Results and Discussion
2.1. Swelling Tests
Figure 1 shows the swelling ratio (SR) profiles of the different batches studied. The maximum
swelling ratio (SRmax) is included for each swelling curve. The curves in Figure 1 show that swelling
and erosion processes are present in most cases. Hydrophilic polymers such as CH, HPMC, and GG
swell when in contact with an aqueous medium as opposed to disintegrating. These batches increase
in size due to the relaxation of the polymer chains. A temperature of 37 ◦C causes a decrease in the
vitreous transition temperature, forming an area where the polymers change from a crystalline to a
rubbery state (known as the gel layer) [36]. It is, thus, possible to distinguish a first stage for the GG
and HPMC batches in which the swelling process takes precedence until the SRmax (96 h) is reached,
followed by the erosion of the formulations. HPMC and GG are significant for having a high SR; this is
higher in the case of GG, which also takes much longer to dissolve completely. GG is well known for
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superabsorbent hydrogels [37]. 
 
















Figure 1. Swelling profile of each batch in simulated vaginal fluid (SVF). Data on the maximum
swelling ratio (SRmax) are indicated.
In c ntrast, CH undergoes mod rate but sustain d swelling and acq ir s an aqueo s volume
of 183% of its weight, corrobora ing the results of Chen t al. [38]. T is is because CH has an
unusual swelling process, and after abo t 48 h the pressure from the gel causes th breakdown
of its core (Figure 2). Fr m the time when the fracture occurs, the core portion which the gel prevented
from swelling is exposed to the aqueous medium and absorbs water, causing a new increase in SR
values (Figure 1). Finally, ERS is not a water-soluble polymer and hardly absorbs water from the
medium—although the porous matrix adsorbs a small amount—and, thus, remains undissolved
throughout the test (19 days). This renders it inadequate, as once the drug has been released, the
compact would need to be removed. In view of the results, the batch with CH would be the most
comfortable, since it undergoes moderate swelling and complete erosion. This factor, the comfort of
women, is crucial for the adherence to the use of the formulation. In this respect there is no problem
since studies show that vaginal tablets are the solid dosage form preferred by women for intravaginal
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administration [39]. In addition, the small size of the compacts developed (2.2–2.3 mm in height)















produces  the gel  layer with  the highest SR  (Figure 1),  it has very  little consistency and  the drug 
diffuses rapidly through it, so it does not represent a delayed release mechanism [41]. However, when 
HPMC and CH compacts are introduced into simulated vaginal fluid (SVF) the outer layers form a 
strong consistency gel, as  reported by other authors, which controls TFV  release  [20]. This  result 
would ensure women were protected against the transmission of HIV for at least 3–4 days (90%–95% 






dependent  methods  (zero‐order,  first‐order,  Higuchi,  Korsmeyer‐Peppas,  Hixson‐Crowell, 
Hopfenberg and Weibull) were used to fit the experimental results. After analysing each batch, the 
models  found  to have  the best  fit  to  the curves  in Figure 3  (high correlation coefficients R2) were 
Korsmeyer‐Peppas and Higuchi and Weibull [43,44]. 
Figure 2. Chitosan compact swelling pattern. First the compact has a given shape (A), although the
upper and lower layers swell in the presence of SFV, exerting pressure on the core (B) until finally this
pressure causes the compact to break (C).
2.2. Release Study
A drug’s release rate from a dosage form can be influenced by different phenomena, ranging
from drug dissolution to water absorption, polymer swelling, and the dissolution and diffusion of the
drug through the polymer network [40]. Figure 3 shows the TFV release profiles corresponding to
the prepared batches. The release data shows that HPMC and CH ar the polymer that best c trol
the drug re eas from the compact. One interesting result is that in the first 48 h these formulations
released lower drug amounts than those containing ERS or GG, owing to the characteristics of ERS and
GG. ERS is an insoluble polymer with pH-independent swelling and low permeability that is unable to
gel in aqueous medium and, thus, barely controls the release of the drug [33]. Although GG produces
the gel layer with the highest SR (Figure 1), it has very little consistency and the drug diffuses rapidly
through it, so it does not represent a delayed release mechanism [41]. However, when HPMC and CH
compacts are introduced into simulated vaginal fluid (SVF) the outer layers form a strong consistency
gel, as reported by other authors, which controls TFV release [20]. This result would ensure women
were protected against the transmission of HIV for at least 3–4 days (90%–95% TFV released). The
inhibitory concentration 50 (IC50) of TFV has been found to be between 1.08–1.22 µM depending on the
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Figure 3. Tenofovir release profiles obtained from different batches in SVF.
In order to investigate the kinetics of TFV release from these formulations, mathematical model
dependent methods (zero-order, first-order, Higuchi, Korsmeyer-Peppas, Hixson-Crowell, Hopfenberg
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and Weibull) were used to fit the experimental results. After analysing each batch, the models found
to have the best fit to the curves in Figure 3 (high correlation coefficients R2) were Korsmeyer-Peppas
and Higuchi and Weibull [43,44].
According to Korsmeyer-Peppas, the drug release as a function of time follows Equation (1):
Mt/M∞ = Ktn (1)
Which can also be expressed as Equation (2):
Ln(Mt/M∞) = Ln(KKP) + nLn(t) (2)
where Mt/M∞ is the fraction of drug released at time t, KKP is a constant incorporating the structural
and geometric characteristics of the compact, and n is the release exponent [44]. In the case of cylindrical
compacts, depending on the n value the drug release could follow a pure diffusion process (n ≤ 0.45),
an anomalous transport with simultaneous diffusion and structural modification of the polymer matrix
(0.45 < n < 0.89), transport case II (n = 0.89) or transport Supercase II (n > 0.89). Both Case II and
Supercase II involve the structural modification of the polymer matrix [43,45].
A good fit to the Higuchi model indicates that the drug diffuses through pores in the polymer
matrix (this process is equivalent to Korsmeyer–Peppas for n ≤ 0.45). The Higuchi equation for fitting
the curves of Figure 3 is in this case Equation (3), where Q is the amount of drug released in time t and














where M is the dissolved drug, M0 is the total amount of drug in the compact and tlag is the lag time, a
is a scale parameter that describes the dependence on time, and b describes the shape of the dissolution
curve [43].
In our case, where there is no lag time (see curves in Figure 3), and because the drug release
profiles have an exponential shape, b is equal to 1. If we take the constant KW = 1/a, then Equation (4)







Figure 4 shows the corresponding fit of the experimental data to these drug release models, and
Table 1 shows the n, KKP, KH, and KW kinetic constants for these three models.
Table 1. TFV release kinetics from HPMC, CH, ERS, and GG batches.
Batch
Korsmeyer-Peppas Higuchi Weibull
KKP n R2 KH R2 KW R2
HPMC 0.088 0.63 0.9899 0.124 0.9980 0.036 0.9931
CH 0.077 0.92 0.9926 0.130 0.9815 0.040 0.9839
ERS 0.152 0.73 0.9887 0.148 0.9453 0.098 0.9859
GG 0.161 0.71 0.9929 0.145 0.9231 0.068 0.9756
According to the data in Table 1, the batches with HPMC and CH have a good fit with the
Higuchi kinetic (Figure 4A). However, the Higuchi kinetic can only be applied when the swelling
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and dissolution of the matrix are negligible [43], so it cannot be used to explain the drug release
behaviour from these batches. All of the batches tested have a good fit to the Korsmeyer–Peppas
kinetic (Figure 4B). The analysis of n values for different batches reveals that those prepared with
HPMC, ERS and GG have similar values of close to 0.7, and that in the case of CH n is higher and
close to 1. It can, therefore, be said that the TFV release from HPMC, ERS, and GG corresponds to an
anomalous (non-Fickian) transport, while for CH—whose n value is over 0.89—it follows a Supercase
II release, a mechanism that implies an extreme drug transport [45]. During polymer swelling the
breakage of the compact occurs because the upper and lower layers of the compact swell to form a gel,
causing a compressive stress on the core that prevents axial swelling. As the gel continues pressing on
the core, the internal compact pressure increases until the core breaks (Figure 2) [46].
The n values for HPMC, ERS, and GG fall in the range 0.45–0.89, indicating that the drug release is
governed by simultaneous structural modification and diffusion through the polymer matrix processes.
In the HPMC and GG batches, the polymer swells at the same time as the drug diffuses through the
gel formed. As has been shown in the swelling test, these two polymers form a long-lasting gel and
the rearrangement of chains occurs slowly; the simultaneous diffusion is the process that causes the
time-dependent anomalous effect [46].
ERS captures very little water, which rules out polymer swelling as a possible explanation. When
the drug release from the ERS batch is fit to the Weibull model, the constant KW is much higher than
for the other polymers—including GG (Figure 4C)—although the differences between GG and ERS
in the other models are insignificant (Figure 4A,B). The Kw values in the Weibull equation represent
the drug release rate constant. HPMC and chitosan have similar KW values that are much lower than
the other two formulations, signalling the greater control over the release of TFV from the compacts
made with these polymers. In contrast, GG and ERS have much higher KW values, since the drug also
diffuses from these compacts at a greater rate. The Weibull model is used to analyse the release profile
of matrix-type drug delivery, and this is the mechanism of TFV release in ERS. This is because ERS is a
permeable polymer that allows water into the compact, followed by the dissolution of the drug in the
medium, and finally the diffusion of TFV through the polymer.
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Figure 4. Fit of TFV release from batches HPMC, CH, ERS, and GG to the Higuchi (A)
Korsmeyer-Peppas (B), and Weibull (C) models.
2.3. Microstructure of Witnesses. FE-SEM, and Hg Porosimetry
It is w ll known that water is removed during freeze-drying of a hydrated polymer system, and
the space that was originally occupied by the solvent is transformed into pores, generating a porous
structure similar to a sponge [47]. As can be seen fr m the micrographs in Figure 5, the witness
microstructures vary considerably depending on the polymer type. Figure 5A, corre ponding to the
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swelling witness of HPMC, has a channelled microstructure formed when water enters the polymer
during swelling. These channels allow the compacts to maintain their shape while the drug diffuses
slowly between them. This perfectly homogeneous microstructure is maintained because HPMC
swelling occurs progressively; the outer layers become swollen but the core remains unswollen until
the outer gel erodes and water reaches the core [48]. This is observed in our release studies, thus, water
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absorbed water between them. This microstructure explains why GG formulations swell the most 



















Figure 5. Electron microscopy micrographs of swollen witnesses of HPMC (A); chitosan (B); Eudragit®
RS PO (C); and guar gum (D).
The micr graph of the CH witness (Figure 5B) shows a sponge-like microstructure with numerous
pores in the polymer through hich the SVF circulates, albeit with difficulty. This result explains the
controlled release of TFV fro CH in spite of its moderate swelling capacity. In contrast, no defined
micr structure is obs rved for the ERS witness (Figur 5C); the formulation has a g ainy microstructure
with different-sized particles, but is unable to swell, which explains the failure of this formulation
to control TFV delivery. Finally, the micrograph of the GG witness (Figure 5D) shows a perfectly
microstructured formulation where the polymer is arranged in parallel sheets with the absorbed
water between them. This microstructure explains why GG formulations swell the most and remain
swollen the longest, as there is a high capacity for very effectively retaining water between these sheets.
However, although the water cannot escape, the drug is able to diffuse through the polymer sheets, so
their ability to retain the drug is minimal.
The above porous microstructures have been characterized by Hg porosimetry. Figure 6 shows
the corresponding pore size distributions (PSD).
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Figure 6. Pore distributions of H , CH, ERS, and GG witnesses.
According to Figure 6, two types of PSD can be described: one has a narrow PSD where most
of the pores re close to 100 µm, while the other has a wide PSD with pores of between 100 and
0.1 µm. Both PSD types are unambiguously associated to the swelling behaviours in Figure 1 and the
FSEM micrographs in Figure 5. The HPMC and GG batches have high swelling characteristics with
well-defined channelled microstructures and produce a narrow PSD with high pore sizes. In contrast,
ERS and CH, with minimal swelling properties and grainy microstructures, produce a wide PSD with
small pore sizes. There are two interesting observations: the first is that while the PSD of the GG batch
also has a small number of pores with sizes between 50 and 10 mm, the PSD of HPMC also has small
pores with sizes between 50 and 0.5 µm; and the other is that the PSD of CH has pores between 10 and
100 µm, while the PSD of ERS is below 50 µm. Thi points to the conclusion that as the compact has
higher swelling properties, the corresponding PSD must have a high pore size.
Table 2 contains a summary of the results obtained from these PSD, and shows that mean pore
size (Dp) values are related to SR values, as mentioned earlier. Hence, the higher the swelling capacity,
the higher the Dp values. However, pore volumes (Vp) are more closely related to the total number of
pores present i the witness, so the lowest Vp correspond to the ERS batch containing the smallest
pore size. The CH witness has a higher Vp value than ERS due to its larger pore size, as indicated by
the Dp. It is followed by GG, with a high Vp value but lower than HPMC, although it has a higher Dp.
Finally, the highest Vp corresponds to HPMC. HPMC’s higher Vp compared to GG is due to the small
pores of between 50 and 0.5 µm in HPMC, but not in GG. In contrast, pore area (Sp) values show the
opposite pattern; namely the higher the Dp, the lower the Sp. This is because pore area increases as
pore volume decreases. As may be expected, porosity (P) values are related to Dp and Vp values, as
porosity increases with both pore size and pore volume. Finally, bulk density (ρB) values are related to
Vp and P values, as ρB corresponds to a sample where pores and material are measured as a whole.
However, apparent density (ρA) corresponds to the sample with no pores over 0.1 µm, i.e., a dense
sample, and these values are characteristic of the chemical sample composition.
Table 2. Pore volume (Vp), pore area (Sp), mean pore size (Dp), bulk and apparent densities (ρB, ρA),
and porosity (P) of HPMC, CH, ERS, and GG witnesses.
Witness Vp (cm3·g−1) Sp (m2·g−1) Dp (µm) ρB (cm3·g−1) ρA (cm3·g−1) P (%)
HPMC 5.97 0.36 91.89 0.14 0.90 84
CH 1.74 0.43 28.74 0.38 1.19 67
ERS 0.35 3.59 9.16 0.77 1.06 27
GG 5.89 0.25 106.08 0.14 0.97 85
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These results show that P, Vp, Dp, and ρB are related to the SRmax of the corresponding batches
(Figure 1), but are not clearly related to the release profiles (Figure 3) or release kinetics (Table 1). Thus,
the following relationship (with R2 = 0.992) has been found between Dp and SRmax:
Dp = 35.4·Ln(SRmax) + 13.4 (6)
This equation indicates that for a polymer with a very low swelling capacity the release of the
TFV drug in aqueous medium causes pores of around 13 µm. In our case the ERS polymer presented
pores with a mean size of 9 µm, close to the value obtained by this equation.
2.4. Evaluation of Mucoadhesion
An analysis of the mucoadhesion results (Figure 7) reveals that HPMC, ERS, and GG formulations
remain attached to the mucosa for extended periods of time, even after all the TFV has been released.
In contrast, the CH formulation shows a good initial adhesion to vaginal mucosa, and a residence time
of about 48 h. This agrees with the results of other studies, highlighting the lower mucoadhesive ability
of CH compared to cellulose derivatives [49]. This seems to be because the bonding to the mucosa by
positively charged groups, as in the case of chitosan, is less durable than bonding through hydrogen
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Figure 7. Mucoadhesion residence time of each batch in SVF.
The other three polymers show longer adhesion times to the mucosa of over 140 h in all cases.
The formulation that remains attached for longest is HPMC, followed by GG and ERS. HPMC has
been studied in depth, and this research corroborates its high mucoadhesive potential, caused by
hydrogen bonding effects [50]. Although the mucoadhesive properties of GG have been poorly studied,
another work shows its mucoadhesive strength is similar to HPMC [51]. Lastly, the most surprising
results derive from the evaluation of the mucoadhesion of ERS, which in the previous literature is
not classified as a mucoadhesive polymer. Our study shows that it has substantial mucoadhesive
properties, and confirms a pr vious study comparing ERS with materials typically reg rded in the
literature as being go d adhesives [52]. The adhesion to mucosa may be du to the presence of the
quaternary ammo ium group, which is pr tonated and may bind to nega ive charges in mucosa.
Although these good mucoadhesion r sults highlight the high binding ability of the polymers, horter
times are required in this case—similar to the time for CH—since the TFV release occurs over a shorter
period and there is no therapeutic justification for retaining the formulation adhered to the patient’s
vaginal mucosa after the drug has been completely released. In addition to discomfort, it could induce
the rejection of the formulation.
2.5. Cell Toxicity
The biocompatibility of the formulations was evaluated through an in vitro cellular toxicity assay.
All of the components of the different formulations were incubated at 37 ◦C in a 5% CO2 atmosphere
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for five days before the assay to ensure that any potential toxic component would be present in the
suspension. MT-2, a lymphoblastoid cell line, and HEC-1A, a uterus-derived cell line, were seeded and
treated with different dilutions of the suspensions. All of the components were tested at a maximum
concentration of 1000 µg/mL in base-5 serial dilutions. Experiments were performed on MT-2 cells to
evaluate toxicity on the immune cells present in vaginal or uterine mucosae, and also on the uterus
epithelial cell line (HEC-1A) to assess any potential damage to the integrity of the mucosae. Cytotoxic
concentration 50 (CC50) were calculated when possible.
As shown in Table 3 and Figure 8, no toxicity was detected at the concentrations tested for
any of the compounds. Interestingly, Tenofovir did not show cytotoxicity even at the highest tested
concentration of 1000 µg/mL (around 3.3 mM).
Table 3. CC50 values of TFV, GG, CH, ERS, and HPMC obtained from the cytotoxicity assay in both
MT-2 and HEC-1A cell lines. CC50: cytotoxic concentration 50%.
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i re 8. Cytotoxic evaluation of TFV, GG, CH, ERS, and HPMC measured in MT-2 cells and
HEC-1A cells.
3. Experimental Section
3.1. Materials and Preparation of the Compact
Tenofovir (TFV, lot: FT104801401, MW: 287.21 g/mol) was supplied by Carbosynth Limited
(Berkshire, UK). Chitosan, with 97% deacetylation and a viscosity of 92 mpa·s (CH, lot: 8826900003),
was provided by Nessler (Madrid, Spain). The molecular weight, 105 g/mol, was estimated
by viscometric measurements. Hydroxypropylmethylcellulose—Methocel® K 100 M (HPMC; lot:
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DT352711, MW: 72 × 104 g/mol) was kindly supplied by Colorcon Ltd. (Kent, UK). Eudragit RS®
(ERS; lot: G120238035, MW: 407.932 g/mol) was supplied by Evonik (Essen, Germany). Guar gum
(GG; lot: SLBH5231V, MW: 22 × 104 g/mol) was acquired from Sigma-Aldrich (Saint Louis, MO, USA).
Magnesium stearate PRS-CODEX (MgSt; lot: 85269 ALP) was acquired from Panreac (Barcelona, Spain).
All other reagents used in this study were of analytical grade and used without further purification.
Demineralized water was used in all cases.
Four batches of compacts were prepared from physical mixtures of the corresponding polymer
(HPMC, CH, ERS, GG), TFV and MgSt. In all cases, each compact contained 290, 30, and 3 mg of
polymer, TFV, and MgSt respectively.
In all cases the compacts were prepared with a press similar to the one used for preparing solid
samples for analysis by IR spectroscopy. A stainless-steel disc was placed in the die, and the physical
mixture of the components was placed on top. A second stainless steel disc was then placed on top.
Five tons of constant pressure was applied using a punch for four minutes. Finally, the piston and the
discs were removed, and the compact was stored in a desiccator until its subsequent evaluation. The




The swelling pattern of the different batches in SVF were analysed using the method described
by Ruiz-Caro et al. [53]. Each analysis was tested in triplicate. Swelling tests were carried out in a
shaking water bath at 37 ◦C and 15 opm. In order to maintain the contact between the compact and
the medium, and for more convenient handling of the samples during the test, each compact was
previously fixed to a stainless steel disc, 3 cm in diameter, with a cyanoacrylate adhesive. At given
time intervals (every hour during the first six hours and once a day for the remainder of the analysis),
the discs were removed from the medium, placed on filter paper to eliminate the liquid excess and







where Cs and Cd correspond to the swollen and dry compact weights, respectively.
3.2.2. Release Study
The method described by Sánchez-Sánchez et al. [20] was used concurrently with the swelling test
to assess the release behaviour of TFV in each batch. Each sample was inserted in a borosilicate glass
bottle containing 80 mL of the SVF [54] and placed in a shaking water bath (Selecta® UNITRONIC320
OR, Barcelona, Spain) at 37 ◦C and 15 opm. Every day at given times, 5 mL samples were removed
and filtered. The medium was replaced with the same volume of SVF at the same temperature. TFV
release concentrations were quantified by UV spectroscopy at a wavelength of 260 nm in a Shimadzu®
UV-1700 spectrophotometer (Kyoto, Japan). The test was performed in triplicate in each case. Studies
have been conducted on the solubility of TFV in SFV at room temperature and the results are 4 mg/mL.
Therefore, this ensures that the release study is performed under sink conditions and the release of
drug is not conditioned by its solubility but by the release system.
The drug release experimental data were fitted to different model-dependent methods (zero
order, first order, Higuchi, Korsmeyer-Peppas, Hixson-Crowell, Hopfenberg, and Weibull models) to
investigate the kinetics of drug release from the various batches [43].
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3.2.3. Swelling Witnesses
In order to characterize the microstructure acquired by the compacts when introduced in the SVF,
swelling witnesses were prepared by determining the time each batch reached the maximum SR. This
was done by attaching two compacts from each batch to the same stainless steel discs used for the
swelling test. The discs were treated in the same way as in the swelling test. They were immersed in
a beaker with SVF which was then placed in the shaking water bath (Selecta®UNITRONIC320 OR,
Barcelona, Spain) (37 ◦C and 15 opm). The compacts were left under these conditions until they reached
the maximum SR. Each compact was then extracted from the medium and lyophilized, and then stored
in a desiccator until analysis. Witness microstructures were analysed by electron microscopy using a
field emission scanning electron microscope (FE-SEM, Hitachi 4700, Tokyo, Japan) at an accelerating
voltage of 15 V. Pore size distributions (PSD) were determined by mercury porosimetry using an
Autopore II 9215 (Micromeritics Corp., Norcross, GA, USA). The corresponding pore volumes (Vp),
pore areas (Sp), mean pore sizes (Dp), bulk and apparent densities (ρB, ρA), and porosities (P) of the
samples were calculated from these PSD, assuming cylindrical pore shapes in all cases.
3.2.4. Assessment of Mucoadhesion
A new ex vivo mucoadhesion test was used to determine how long the compact remained
adhered to the vaginal mucosa. A sample of freshly excised veal vaginal mucosa (obtained from a
local slaughterhouse) was fixed with a cyanoacrylate adhesive to an 8.5 cm × 5 cm stainless steel
plate (SSP). Each compact was then adhered to the mucosa, applying a given pressure (500 g for 30 s).
The SSP was placed at an angle of 60◦ inside a beaker containing 150 mL of SVF, and this system
was inserted in the shaking water bath (Selecta® UNITRONIC320 OR, Barcelona, Spain) at 37 ◦C
and 15 opm. The bioadhesion time of each batch was assessed by visual observation of the samples.
All batches were tested in duplicate.
3.2.5. Cytotoxicity Assessment
Two human cell lines were used: a lymphoblastic cell line, MT-2 [55] and a uterus/endometrium
epithelial cell line, HEC-1-A (kindly provided by M. A. Muñoz, Hospital Gregorio Marañón, Madrid,
Spain). Both cells were grown in RPMI 1640 medium supplemented with 10% (v/v) foetal bovine
serum, 2 mM L-glutamine and 50 µg/mL streptomycin at 37 ◦C with a humidified atmosphere of 5%
CO2. HEC-1-A cells were detached by treatment with a trypsin 0.25% and EDTA 0.03% solution. Cell
cultures were split twice a week.
Cell toxicity was measured by the CellTiter Glo viability assay (Promega). Briefly, GG, CH, ERS,
HPMC, and TFV were suspended in water at a concentration of 10 mg/mL and left in culture (5% CO2
and 37 ◦C) for five days [56]. Cells were then seeded in 96 microwell plates at a density of 1 × 105 cells
per well in the case of MT-2, and 2 × 104 in the case of HEC-1-A, in complete RPMI medium, and
treated with fresh medium containing different concentrations of suspensions (1000, 200, 40, 8, 1.6,
and 0.32 µg/mL), or with the same concentration of vehicle (water). After 48 h of incubation, cell
viability was measured following the manufacturer’s instructions (CellTiter Glo viability assay), and
RLUs were obtained in a luminometer. Data were normalized using RLUs obtained from cells treated
with vehicle (100%) as a reference. Values of CC50 were calculated using GraphPad Prism Software
(non-linear regression, log inhibitor versus response).
4. Conclusions
Vaginal compacts can be a very useful tool for the prevention of HIV transmission from men to
women. Adherence to the use of microbicides has been one of the main drawbacks in demonstrating
the efficacy of the formulations studied to date. In contrast, these compacts would decrease the
frequency of administration by achieving sustained release of the drug over several days, resulting in
a greater adherence to the treatment.
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From the results obtained it can be concluded that there are two polymers (CH and HPMC) with
the potential to achieve sustained and complete release of TFV from vaginal mucoadhesive compacts.
However, the good bioadhesive properties of CH, which allow the formulation to remain attached
to the vaginal mucosa only until all of the drug has been released, its moderate SR, which ensures
more comfort for the patient than the other polymers tested, and its low cytotoxicity warrants that
CH compacts containing TFV have proven to be a suitable formulation for the prevention of sexual
transmission of HIV.
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